Home » Newsletters » BioWorld Science

BioWorld Science

June 21, 2019

View Archived Issues

Spreading out DDR inhibitors keeps efficacy, reduces toxicity

Lectin is risk factor for yeast infections

Dying microglia rejuvenate myelin

Bone from iPSCs

Kleo Pharmaceuticals selects first clinical candidate from PeptiDream collaboration

Efficacy and safety of nivolumab in advanced refractory biliary tract cancer

Efficacy and safety of PD-L1 inhibitor durvalumab in HIV+ patients with advanced solid tumors

Upregulation of STARD1 following endoplasmic reticulum stress mediates acetaminophen hepatoxicity

FDA allows ReNetX's IND for first-in-human study of AXER-204 to treat spinal cord injury

Arbutus receives regulatory clearance to begin phase Ia/Ib study of AB-729

Cyxone announces initiation of first-in-human trial of T20K for the treatment of MS

FDA issues complete response letter on use of Bronchitol for adult patients with cystic fibrosis

Zhejiang University describes mRNA methyltransferase-deficient mumps viruses

Guangzhou Bio-gene Technology presents CAR T cells comprising CXCR5

MYBPC1 gene mutations tied to tremor-associated myopathy

New creatine prodrugs disclosed by Ultragenyx Pharmaceutical

Bristol-Myers Squibb, Allied-Bristol Life Sciences patent EPRS inhibitors

Chinese PLA General Hospital patents compositions comprising bacillus Oscillibacter valericigenes

Distal motor neuropathy found associated with mutations in GBF1 gene

Pancreatic cancer biomarker turns out to be disease driver

Orion's OB-002 equivalent to anti-PD-1 antibody in preclinical colorectal cancer model

PAOPA displays varied antiparkinsonian activity in vivo

Phase II proof-of-concept study of REGN-3500 in asthma meets primary endpoint

European Commission approves Esperoct for adolescents and adults with hemophilia A

ArTara Therapeutics begins development of TARA-002

Medicenna Therapeutics reports promising preclinical data on MDNA-109

Ritter updates progress of phase III trial of RP-G28 for lactose intolerance

Phase I results justify phase II for CuATSM in Parkinson's disease

Gracell reports preliminary results from pilot study of GC-007F for B-ALL

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Dec. 5, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Dec. 5, 2025.
Epigenetic technology could eliminate misfolded prion proteins
BioWorld Science
The number of deaths caused by prion diseases reaches about 30,000 annually. Only 5 months pass from the diagnosis of seemingly healthy patients to the fatal...
Mesothelin is biomarker, potential target in arthritic bone damage
BioWorld Science
In a recent study published in Cell Reports Medicine, researchers from the Institute of Chinese Materia Medica of the China Academy of Chinese Medical Sciences...
Gene therapies aim for the big goal of edits in vivo
BioWorld Science
The field of gene therapy is experiencing major advances driven by precise editing technologies, such as base and prime editing, and by the design of increasingly...